Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Annika Fendler¹, Scott T C Shepherd², Lewis Au², Mary Wu³, Ruth Harvey⁴, Andreas M Schmitt⁵, Zayd Tippu², Benjamin Shum², Sheima Farag⁵, Aljosja Rogiers⁵, Eleanor Carlyle⁵, Kim Edmonds⁵, Lyra Del Rosario⁵, Karla Lingard⁵, Mary Mangwende⁵, Lucy Holt⁵, Hamid Ahmod⁵, Justine Korteweg⁵, Tara Foley⁵, Taja Barber¹, Andrea Emslie-Henry¹, Niamh Caulfield-Lynch¹, Fiona Byrne¹, Daqi Deng¹, Svend Kjaer⁶, Ok-Ryul Song³, Christophe Queval³, Caitlin Kavanagh³, Emma C Wall⁷, Edward J Carr⁸, Simon Caidan⁹, Mike Gavrielides¹⁰, James I MacRae¹¹, Gavin Kelly¹², Kema Peat⁵, Denise Kelly⁵, Aida Murra⁵, Kayleigh Kelly⁵, Molly O'Flaherty⁵, Robyn L Shea¹³, Gail Gardner¹⁴, Darren Murray¹⁴, Nadia Yousaf¹⁵, Shaman Jhanji¹⁶, Kate Tatham¹⁶, David Cunningham¹⁷, Nicholas Van As¹⁸, Kate Young⁵, Andrew J S Furness¹, Lisa Pickering⁵, Rupert Beale¹⁹, Charles Swanton²⁰, Sonia Gandhi²¹, Steve Gamblin²², David L V Bauer²³, George Kassiotis²⁴, Michael Howell³, Emma Nicholson²⁵, Susanna Walker¹⁶, James Larkin⁵, Samra Turajlic²⁶; CAPTURE consortium

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
⁴ Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
⁵ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
⁶ Structural Biology Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
⁷ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK.
⁸ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
⁹ Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London, UK.
¹⁰ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹¹ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹² Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
¹³ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK; Translational Cancer Biochemistry Laboratory, Institute of Cancer Research, London, UK.
¹⁴ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁶ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁷ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁸ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London, UK.
²⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²¹ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, London, UK.
²² Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²³ RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁴ Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁵ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁶ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, Institute of Cancer Research, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 35090602
PMCID: PMC8789238
DOI: 10.1016/S0140-6736(22)00147-7

Comment

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Annika Fendler et al. Lancet. 2022.

. 2022 Mar 5;399(10328):905-907.

doi: 10.1016/S0140-6736(22)00147-7. Epub 2022 Jan 25.

Authors

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
⁴ Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
⁵ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
⁶ Structural Biology Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
⁷ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK.
⁸ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
⁹ Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London, UK.
¹⁰ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹¹ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹² Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
¹³ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK; Translational Cancer Biochemistry Laboratory, Institute of Cancer Research, London, UK.
¹⁴ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁶ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁷ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁸ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London, UK.
²⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²¹ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, London, UK.
²² Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²³ RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁴ Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁵ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁶ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, Institute of Cancer Research, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 35090602
PMCID: PMC8789238
DOI: 10.1016/S0140-6736(22)00147-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

DC has received institutional grant funding from MedImmune/AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, Leap, Roche. DLVB has received grant funding from AstraZeneca. CS is funded by CRUK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), the CRUK Lung Cancer Centre of Excellence (C11496/A30025), the Rosetrees Trust, Butterfield and Stoneygate Trusts, the Novo Nordisk Foundation (ID16584), a Royal Society Professorship Enhancement award (RP/EA/180007), the National Institute of Health Research (NIHR) Biomedical Research Centre at University College London Hospitals, the CRUK University College London Centre, the Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation (BCRF 20-157). This work was supported by a Stand Up To Cancer‐LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational research grant (SU2C-AACR-DT23-17 to SMD and AES). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. CS received an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme (835297). CS is a Royal Society Napier Research Professor (RP150154). ST is funded by Cancer Research UK (A29911); the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC10988), the UK Medical Research Council (FC10988), and the Wellcome Trust (FC10988); the NIHR Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), the Royal Marsden Cancer Charity, The Rosetrees Trust (A2204), Ventana Medical Systems (grant reference numbers 10467 and 10530), the National Institute of Health (U01 CA247439) and Melanoma Research Alliance (686061). ST has received speaking fees from Roche, Astra Zeneca, Novartis, and Ipsen. ST has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. All other authors declare no competing interests. AF, STCS, LA, MW, and RH contributed equally.

Comment on

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Shum B, Gerard CL, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C; Crick COVID19 consortium; Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S; CAPTURE consortium. Fendler A, et al. Cancer Cell. 2022 Feb 14;40(2):114-116. doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29. Cancer Cell. 2022. PMID: 34968417 Free PMC article. No abstract available.

References

1. Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer. 2021 doi: 10.1038/s43018-021-00274-w. published online Oct 27. - DOI - PMC - PubMed
1. Fendler A, Shepherd STC, Au L, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer. Cancer Cell. 2022 doi: 10.1016/j.ccell.2021.12.013. published online Dec 29. - DOI - PMC - PubMed
1. Cele S, Jackson L, Khoury D, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021 doi: 10.1038/s41586-021-04387-1. published online Dec 23. - DOI - PMC - PubMed
1. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Research Square. 2021 doi: 10.21203/rs.3.rs-1168453/v1. published online Dec 27. (preprint). - DOI - PMC - PubMed
1. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2021 doi: 10.1056/NEJMc2119358. published online Dec 29. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Affiliations

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical